product approval introduction

FDA Approves Myrbetriq Combo Treatment for Overactive Bladder

The Food and Drug Administration (FDA) has approved Myrbetriq (mirabegron extended-release tablets; Astellas) in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. In clinical trials, the combination of Myrbetriq + solifenacin succinate was associated with greater improvements in the number of incontinence episodes per 24 hours (primary endpoint), the number of micturitions per 24 hours (primary endpoint), and the volume voided per micturition (secondary endpoint) compared to placebo or to individual active components. Long-term data also demonstrated that the effects of combination treatment were maintained throughout a 1-year treatment period. Read more.

Source: MPR, April 30, 2018

hormones change as women age

When Bathroom Runs Rule the Day (and Night)

I have only one regret about not having been born a male, and it concerns plumbing, namely how easy it is for men to eliminate liquid waste,  whether by avoiding long bathroom lines or being able to relieve themselves discreetly when no facility is available.  My male envy grew after I contracted poison ivy on unmentionable parts when nature called during a hike in the woods. Urination has long been a vexing problem for women.  Read more.

Source: New York Times, December 12, 2016